Key Highlights

● A German lender initiated coverage of Novartis with a hold rating and no price target.

● Novartis reported Q3 EPS of $2.46 versus a $2.25 consensus on Oct. 27.

● Third-quarter Revenue was $15.03 billion, up 4.4% from a year earlier.

● Sanofi gained 5.4% in Paris after beating expectations and raising its outlook.

Novartis (NYSE:NVS) is drawing attention on Friday after a German lender initiated coverage of the Swiss drugmaker with a "hold" rating. A market-data report on Oct. 30 described the move, citing another source, and said the research note was dated Wednesday. No price target was disclosed.

A hold rating does not tell investors to buy or sell. It adds to a cautious tone on the stock: one data tally shows six buy ratings, ten holds and two sells, for a consensus rating of "Hold" and an average price target of $152.25.

No pre-market move for Novartis's US-listed shares was available in the sources reviewed as of about 8:30 a.m. ET Friday, so the stock is on watch rather than moving in a confirmed direction.

Fresh off a quarterly beat

The initiation comes days after Novartis reported third-quarter results on Tuesday, Oct. 27. According to market data, Earnings Per Share were $2.46, beating the $2.25 consensus. Revenue was $15.03 billion against an estimated $14.53 billion, up 4.4% from a year earlier.

Market data put Novartis's Market Value at about $307 billion, with a price-to-earnings ratio of about 30.7. The shares have traded between $121.98 and $170.46 over the past 52 weeks. The 50-day Moving Average was $148.32 and the 200-day average $151.71. Analysts expect earnings of $8.94 a share for the current fiscal year, according to market data.

The same data show a Business with high profitability and a defensive trading profile. They list a net Margin of about 18.1%, a Return on Equity of about 41%, and a Beta of 0.41. That means the stock has historically moved far less than the overall market, which helps explain its appeal on a volatile day.

Other Brokers have moved recently. One brokerage upgraded the stock from "reduce" to "hold" in September and raised its target to $136. Another cut its target to $130 from $147, also with a hold rating. A third has reiterated a "buy", while a fourth restated a "sector perform" rating on Wednesday and a fifth reaffirmed "neutral" in July, according to market data.

Novartis focuses on prescription medicines in cardiovascular, renal and metabolic disease, immunology, neuroscience, oncology and hematology. Its key products include the heart-failure drug Entresto, the immunology drug Cosentyx, the breast-cancer treatment Kisqali, the multiple-sclerosis drug Kesimpta, the cholesterol drug Leqvio and the radioligand cancer therapy Pluvicto. Its ADRs trade on the New York Stock Exchange and are part of the NYSE Composite.

Pharma's moment in a tech selloff

The backdrop is friendly to big drugmakers. Market data at roughly 8 a.m. ET showed Nasdaq-100 futures down 2.6% and S&P 500 futures down 1.1%, as worries about AI spending hit tech after Amazon (NASDAQ:AMZN)'s and Intel (NASDAQ:INTC)'s results. Dow futures were flat as money rotated into health care and energy.

European peers are rising on Friday. Sanofi (NASDAQ:SNY) gained 5.4% in Paris after beating expectations and raising its outlook, according to media reports. An 8:23 a.m. ET pre-market snapshot showed GSK (NYSE:GSK)'s ADRs up 2.71% and Sanofi's up 3.92%.

Risks and what to watch

The German lender's hold rating reflects the debate around Novartis. Its valuation has risen with the shares near the top of their 52-week range. Generic competition is eroding US sales of Entresto, and US drug-pricing policy and pharmaceutical tariffs remain uncertain.

Watch for the details behind the lender's call and for how Novartis trades relative to the European pharma group after the 9:30 a.m. ET open. The next company-level catalysts are pipeline readouts and Novartis's fourth-quarter results early next year. Tuesday's US midterm elections could also shift expectations for drug-pricing policy.